Cellectis (CLLS)

• Market cap: $301M
• 1 day: -5.68%
• 5 days: -9.39%
• 1 month: -5.97%
• 3 months: -16.71%
• 6 months: -29.81%
• Year to date: -37.71%
• 1 year: 81.21%
• 5 years: -80.81%
• 10 years: -88.39%
• Sector: Healthcare
• Industry: Biotechnology

About: Cellectis SA is a clinical stage biotechnological company, employing the core proprietary technologies to develop products based on gene-editing, with a portfolio of allogeneic Chimeric Antigen Receptor T-cells, or UCART, product candidates in the field of immuno-oncology and gene-edited hematopoietic stem and progenitor cells, or HSPC product candidates in other therapeutic indications.

Employees: 229